ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

Is Pharmaceutical Marketing Ethical?

Maduabuchukwu Augustine Onwuzurike
[1.] Higher National Diploma In Marketing
(Federal Polytechnic Nekede, Owerri, Imo State, Nigeria)
[2.] Master's Degree In Business Administration
(Lincoln University, Oakland, California, USA)

Augustine Rita Chikodi
Higher National Diploma In Public Administration
(Abia State Polytechnic Aba, Abia State Nigeria)

Abstract:- The pharmaceutical industry is expanding, and there are many new scientific breakthroughs in the modern day. As a result, moral concerns sparked by marketing strategies have led to intense global debates. Pharmacies are trying to market their products and maintain their competitiveness, raising concerns about potential conflicts between corporate interests and the fundamentals of medical ethics. This article takes a multidisciplinary approach, incorporating public health, bioethics, and regulatory frameworks to begin a thorough investigation of the complex ethical landscape surrounding pharmaceutical marketing. The background section shows how pharmaceutical marketing methods have evolved by closely examining empirical evidence and ethical perspectives. It demonstrates how the significant move toward direct-to-consumer advertising (DTCA) has altered the healthcare industry's operations. To illustrate how intricate modern marketing strategies are, the article closely examines various techniques, including sponsorships, patient assistance programs, physician detailing, and promotional materials. The piece's primary focus is its in-depth analysis of ethics, founded on the fundamental ideas of beneficence, justice, non-maleficence, and respect for individual liberty. Pharmaceutical marketing has been scrutinized ethically for an extended period. Opponents argue that practices such as advertising and compensating doctors to promote specific treatments are considered to breach medical ethics. Advocates argue that the current methods are beneficial for education and can be ethically utilized with adequate regulation. This study examines the various perspectives in the ongoing debate.

Critics argue that drug marketing results in an excessive number of prescriptions for unnecessary medications. False information about diseases is circulated to create the perception that common illnesses require pharmacological treatment. Studies indicate that exposure to marketing is associated with increased prescription rates and expenses, with no apparent health advantages for the general population. Gifts and incentives provided to doctors for marketing purposes are viewed as manipulative and compromising the impartial examination of facts. Detailers advocate for expedited utilization of new medications before their efficacy and safety profiles are fully understood. Some argue that direct-to-consumer advertising prioritizes patients' desires over doctors' professional judgment. High marketing expenses, which are transferred to prescription pricing, create obstacles for individuals to get essential medications.

Associates view marketing as a way to raise awareness for overlooked disorders and educate doctors about novel therapies. Advocates of marketing argue that false advertising is against the law and that physicians rely mostly on medical research when utilizing promotions. According to polls, numerous doctors believe that marketing does not influence them. Supporters also cite evidence indicating that patients are adhering more strictly to healthcare norms, and they argue that warnings provide patients with sufficient information to make informed judgments. Profits are used to fund future research projects that must be commercialized before the patent expires. Both parties utilize substantial evidence while also depending on assumptions regarding impacts. Critics argue that the objectives of marketing are inherently unethical in contrast to evidence-based prescribing. Advocates argue that with careful supervision, appropriate utilization is achievable, albeit adjustments may be necessary. There is limited research demonstrating the definitive effects of something as either harmful or beneficial. Choosing the correct strategy remains a challenging process that requires making compromises. Creating ethically good norms requires meticulous effort to prevent misconduct while also allowing for the dissemination of knowledge. This problem warrants a thorough examination from both an empirical and normative perspective.

Keywords:- *Pharmaceutical Marketing, Ethics, Direct-To-Consumer Advertising, Informed Consent, Healthcare Regulations, Conflicts Of Interest, Patient Autonomy, Beneficence, Non-Maleficence, Global Public Health, Bioethics.*

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

I. INTRODUCTION

In recent years, pharmaceutical marketing has become essential to modern healthcare, sparking much discussion and ethical scrutiny. This practice has many parts, and pharmaceutical companies use them to market their products and stay ahead of the competition in the growing global pharmaceutical business (Smolynets et al., 2016). From direct-to-consumer advertising (DTCA) efforts to physician detailing, sponsorships, and patient assistance programs, pharmaceutical marketing has much reach and affects many parts of healthcare and decision-making (Rollins & Perri, 2014).

Pharmaceutical marketing aims to get the word out about pharmaceutical products, make healthcare professionals and consumers more aware of them, and eventually increase sales and market share (Bélisle-Pipon, 2022). People are furious about the moral issues that these practices raise because they walk a fine line between making money and following basic medical ethics rules (Sillup & Porth, 2008). The current trends in pharmaceutical marketing show that the world is changing quickly. Some areas now allow pharmaceutical companies to directly target consumers through TV, print, and digital platforms (Limbu & Huhmann, 2022). Direct-to-consumer advertising (DTCA), which used to be controversial, has become widely accepted nationwide. People have praised this method for its ability to teach and empower patients, giving them the knowledge to have meaningful conversations with their healthcare providers. However, some people are worried that false or confusing claims could trick patients into changing their minds and hurt the trust between the patient and doctor (Sillup & Porth, 2008).

As a long-standing practice, pharmaceutical reps visit doctors and nurses to discuss their goods, give samples, and build relationships (Rollins & Perri, 2014). This is called "physician detailing." This method is meant to teach doctors and encourage prescribing based on evidence. Still, some people are worried that it could lead to conflicts of interest, biased information, and financial incentives having too much effect on prescribing choices (Limbu & Huhmann, 2022).

Also, drug companies often fund medical education and study projects, which help science move forward and create new medicines. However, this method has been looked at closely because it could lead to undue influence, publication bias, and putting business interests ahead of objective scientific research (Sillup & Porth, 2008). Pharmaceutical marketing practices are at the centre of a critical ethical discussion because they affect patients' health, trust in the healthcare system, and the honesty of medical decisions (Bélisle-Pipon, 2022). Supporters say that responsible marketing can help educate patients, support public health efforts, and make it easier for people to get treatments that could save their lives. On the other hand, critics say that unethical marketing can take away patients' rights, make healthcare more unequal, and hurt trust in the medical field and the pharmaceutical business (Limbu & Huhmann, 2022). This piece aims to give a thorough and nuanced look at the ethical issues related to pharmaceutical marketing by carefully looking at real-world data, ethical theories, regulatory frameworks, and case studies. It aims to promote a balanced discussion by looking at different points of view and counterarguments. It also provides evidence-based suggestions for moral and responsible marketing practices that align with the highest standards of medical ethics and help public health efforts worldwide (Limbu & Huhmann, 2022; Sillup & Porth, 2008). Thus, if pharmaceutical marketing is carried out with integrity, transparency, and a dedication to moral principles, it can be moral and beneficial for society.

II. PHARMACEUTICAL MARKETING

- *Background*

When the pharmaceutical industry began expanding in the early 1900s, it attempted to persuade medical professionals to purchase its goods (Rollins & Perri, 2014). This is the origin of pharmaceutical marketing. Initially, most marketing initiatives were directed toward physician detailing, which required pharmaceutical representatives to see physicians to discuss their products and establish rapport (Sillup & Porth, 2008). While this approach effectively reached medical experts, it had little impact on educating and increasing consumer understanding.

Stringent laws and morality prohibited direct-to-consumer advertising (DTCA) during this period, severely restricting pharmaceutical marketing (Ventola, 2011). Pharmaceutical businesses relied on conferences, industry magazines, and medical journals to spread the word about their goods. Since they are the ones who choose which medications to give, they primarily target healthcare professionals (Lemmens & Hamburg, 2022).

The introduction of direct-to-consumer advertising (DTCA) in the late 20th century significantly altered how pharmaceuticals were promoted. Pharmaceutical companies can now reach customers directly via print, digital, and television media (Limbu & Huhmann, 2022). Initially prevalent in just a few nations, this practice has since spread globally. When the US passed DTCA in the 1990s, it became a pioneer in this field. Since then, legislation governing or restricting these types of advertising activities to varying degrees has been passed in numerous nations. Healthcare The upsurge of DTCA has attracted heated debate among health professionals, legislatures, and consumer organizations (Bhutada et al. , 2022). Critics of the Direct Therapeutic Care Act (DTCA) argue that those in support of this act believe that giving patients information about treatments will somehow liberate the patients. This can mean that patients assume more care responsibilities and also be more informed while engaging with their physicians (Bélisle-Pipon, 2022).

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

Also, as per the existing perception, the use of DTCA may raise public consciousness regarding specific medical disorders; hence, the person can obtain a quicker diagnosis and treatment, which should prove beneficial for public health in the long run (Datta & Dave,, 2017). However, those who do not support DTCA have not remained silent, voicing their concerns on many occasions. This is one of the major problems because advertisements may provide misleading or exaggerated information that may change patient's decision involuntarily and make them pushing for prescription medicaments that they should not or at least do not need (Sillup & Porth, 2008; Ventola, 2011). Furthermore, it has also been postulated that DTCA might negatively affect the patient-physician relationship on grounds that patients get inclined to diagnose themselves and approach their physicians for prescription drugs supported by inadequate information other than that bestowed by the physician (Limbu & Huhmann, 2022; Lemmens & Hamburg, 2022). As expected by some sources, DTCA might increase healthcare costs by initiating the consumption of brand-name medications instead of cheaper generic drugs and causing the costs of treatment to rise (Datta and Dave, 2017; Ventola, 2011). Also, there are some who argue that DTCA may work in the interest of some communities and not others, leading to ehtnopharmacogenomics and therefore increased concentrations of health inequality and inequal access to healthcare (Bhutada et al. , 2022).

Therefore, whereas DTCA is a long established area of discussion in the United States, the broader debate about chemical marketing has recently become a world issue with the continued emergence of pharmaceutical marketing. Some countries such as the US and New Zealand adopted DTCA mainly by educating and empowering Patients on what Weismuller, Smolynets, and Egorov stated as keypositive consequences of the type of advertising while the EU and Canada have either banned this type of advertising or have stringent rules against it out of concern of potential ethical issues and their impacts on the health of the general public. Lemmens & Hamburg, 2022). Examining the moral implications of pharmaceutical marketing has become even more crucial because of its worldwide character, several DTCAs, and various national regulatory frameworks (Bhutada et al., 2022). Pharmaceutical corporations need help to strike the correct balance between their commercial objectives and the fundamental moral principles that safeguard patients' well-being, their right to privacy, and the integrity of the healthcare system.

In addition to DTCA, pharmaceutical corporations have employed various other marketing strategies, including patient assistance programs, physician detailing, and sponsorships. There are ethical considerations unique to each of them (Rollins & Perri, 2014; Sillup & Porth, 2008). For a long time, pharmaceutical salespeople have been going to doctors to discuss their products, offer samples, and establish rapport (Lemmens & Hamburg, 2022). We refer to this as "physician detailing." Although this approach aims to educate physicians and promote evidence-based prescribing, some are concerned that it may result in conflicts of interest, inaccurate information, and financial incentives having an excessive influence on medical decisions (Limbu & Huhmann, 2022). Furthermore, pharmaceutical firms regularly support medical research and education initiatives, which advances science and leads to the development of novel therapies (Bélisle-Pipon, 2022). However, this approach has been thoroughly examined due to the possibility of undue influence, publishing bias, and prioritizing commercial interests above impartial scientific research (Sillup & Porth, 2008; Lemmens & Hamburg, 2022). The international landscape of pharmaceutical marketing has become even more complex due to the various strategies and regulations used for drug promotion in various nations. This has increased the significance of carefully examining the moral concerns raised by these methods. Pharmaceutical corporations need help to strike the correct balance between their commercial objectives and the fundamental moral principles that safeguard patients' well-being, their right to privacy, and the integrity of the healthcare system.

- *The Shift towards Direct-to-Consumer Advertising (DTCA)*

Direct-to-consumer advertising (DTCA) has been a significant step forward in the history of pharmaceutical marketing. Pharmaceutical businesses can directly target customers through TV, print, and digital platforms (Limbu & Huhmann, 2022; Ventola, 2011). This method has gained much popularity around the world. The US was the first country to use DTCA in the 1990s. Since then, other countries have put different levels of rules or limits on these kinds of advertising (Lemmens & Hamburg, 2022). Healthcare workers, policymakers, and consumer advocacy groups are all furious about the rise of DTCA. Supporters of DTCA say that it gives patients more power by giving them information about available treatments. This lets them have more informed conversations with their doctors and make more choices about their care (Bélisle-Pipon, 2022; Datta & Dave, 2017). DTCA is also thought to make people more aware of some medical conditions, which could lead to faster diagnosis and treatment, which is good for public health in the long run. However, some people are apprehensive that DTCA ads might use false or exaggerated claims that could affect patients' choices and cause them to demand certain medications they do not need or should not have (Sillup & Porth, 2008; Ventola, 2011). Concerns have also been raised that DTCA could hurt the relationship between patients and doctors by encouraging patients to self-diagnose and ask for medications based on incomplete information instead of trusting their healthcare providers' knowledge and professional judgment (Limbu & Huhmann, 2022; Lemmens & Hamburg, 2022)

- *Current Pharmaceutical Marketing Strategies*

Advertising and marketing materials, such as print, internet, and TV ads, DTCA is now an essential part of pharmaceutical businesses' marketing plans, and they use a variety of print, digital, and broadcast materials to get the word out. These ads aim to make people more aware of certain

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

medicines, highlight their benefits, and change their minds about what they want to buy (Datta & Dave, 2017; Ventola, 2011). However, some people are worried that these ads might give you false or biased information, not tell you about possible side effects or reasons not to use the product, and encourage you to medicate average human experiences (Bhutada et al., 2022; Lemmens & Hamburg, 2022).

Physician Detailing (visits by drug reps to promote their products) Pharmaceutical reps have been visiting doctors for a long time to talk about their goods, give samples, and build relationships (Rollins & Perri, 2014; Sillup & Porth, 2008). This is called "physician detailing." This method is meant to teach doctors and encourage prescribing based on evidence. However, some people are worried that it could lead to conflicts of interest, biased information, and financial incentives having too much effect on prescribing decisions (Limbu & Huhmann, 2022; Lemmens & Hamburg, 2022).

Grants and sponsorships for medical research and education Scientific progress and the creation of new medicines are helped by pharmaceutical companies' support of medical education and study projects (Bélisle-Pipon, 2022). However, this method has been looked at closely because it could lead to undue influence, publication bias, and putting business interests ahead of objective scientific research (Sillup & Porth, 2008; Lemmens & Hamburg, 2022).

Free samples and programs to help patient's Pharmaceutical companies use patient assistance programs and give away free samples to make their goods easier for people to get and to keep patients coming back (Ventola, 2011). These programs can help patients who might not be able to afford their medicines otherwise, but some people are worried that they could lead to unfair prescribing and the push for more expensive brand-name drugs over cheaper generic ones (Bhutada et al., 2022; Datta & Dave, 2017).

Table 1: Global Trends in DTCA and Related Ethical Concerns

Country/Region	DTCA Regulations	Ethical Concerns
United States	Permitted with FDA oversight	Misleading claims, undermining patient-physician relationship, driving up healthcare costs, promoting medicalization
European Union	Largely prohibited, with some exceptions	Potential conflicts with ethical principles, risk of compromising public health
Canada	Prohibited with some exceptions	Concerns over patient safety, healthcare disparities, and conflicts of interest
New Zealand	Permitted with strict regulations	Potential for biased information, undue influence on prescribing practices
Australia	Permitted for certain products with regulations	Risk of overmedication, promotion of brand-name drugs over generics
Asia-Pacific	Varying regulations across countries	Lack of consistent regulatory frameworks, cultural and social implications



Fig 1: Ethical Concerns Related to Pharmaceutical Marketing Practices
Source: (Bhutada, 2023).

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

There needs to be a careful balance between business interests and basic morals that protect patients' health, their right to privacy, and the dignity of the healthcare system as the global pharmaceutical marketing scene changes. To solve the ethical problems that come up with DTCA and other marketing strategies, we need solid regulatory frameworks, self-regulation by the industry, and ongoing communication between all stakeholders to make sure that practices are responsible and ethical and put patient welfare and public health first (Bhutada et al., 2022; Limbu & Huhmann, 2022; Lemmens & Hamburg, 2022).

- *Arguments That Pharmaceutical Marketing is Unethical*

Pharmaceutical marketing is an intricate and varied task that has generated significant debate on its ethical implications. Some argue that the marketing practices of pharmaceutical firms are immoral and should be restricted or prohibited. Conversely, proponents argue that these practices provide valuable information to patients and clinicians, thereby improving healthcare. Four primary arguments form the basis of the assertions that pharmaceutical advertising is unethical. Marketing increases consumer demand, resulting in excessive prescriptions for unnecessary medications. Secondly, there is concern that marketing tactics such as gifts and rewards may impede doctors' ability to make impartial medical judgements. Direct-to-consumer advertising increases the likelihood of patients requesting medications that may not be suitable for them, diminishing doctors' authority. Finally, opponents argue that the expenses associated with marketing and advertising pharmaceuticals are significant and are ultimately transferred to consumers in the form of increased drug prices, which can hinder access to necessary medications (Cousins, 2009).

- *Over prescription of Unneeded Medications*

One primary argument against pharmaceutical marketing is that it might result in excessive usage and prescription of pharmaceuticals that may not be beneficial or suitable for many people. Khowaja and Feroz (2020) state that disease awareness programmes and branding tactics are employed in pharmaceutical marketing to increase medication usage and patient acquisition. Some argue that this exacerbates common ailments, results in excessive diagnoses, and leads to unnecessary medication for individuals who could benefit from lifestyle changes or for whom medication is ineffective (Mulinari, 2016).

Impotence was not typically treated medically before the development of erectile dysfunction medicines, as it was believed to be a natural aspect of ageing. Erectile dysfunction is increasingly seen as a medical issue requiring drug therapy due to the introduction and extensive promotion of medications such as Viagra and Cialis (Moynihan et al., 2002). Critics view this as evidence that marketing influences individuals' perceptions of health to increase pharmaceutical sales rather than addressing genuine medical necessity. Drug advertising has been criticised for increasing the number of prescriptions for antidepressants, osteoporosis medications, and cholesterol drugs.

An investigation revealed that over 80% of medications advertised directly to consumers did not provide significant additional benefits compared to alternative options. This indicates a disparity between drug advertising and therapeutic efficacy (Kesselheim et al., 2015). A comprehensive review discovered a correlation between pharmaceutical advertising and an increase in prescriptions for advertised drugs, as well as a rise in total prescribing volume and expenditures. This statement remains valid even considering new medications and changes in illness prevalence (Spurling et al., 2010). Multiple studies demonstrate that overprescribing medications is a genuine problem driven mainly by marketing rather than therapeutic necessity.

- *Undermining Objective Medical Decision-Making*

Critics point out that pharmaceutical marketing not only encourages people to abuse drugs but also makes it harder for doctors to make decisions based on facts and proof. Promotional techniques like detailing make this possible. In this method, drug sales reps give doctors gifts, free samples, meals, and other incentives to get them to recommend their drugs. For instance, many studies have shown that physician detailing makes doctors prescribe new, heavily marketed drugs more quickly than older, maybe safer ones (Datta & Dave, 2017).

Also, detailing has been shown to reduce the prescription of generic drugs in favour of brand names. One example is that doctors who got many detailed visits had much lower rates of generic scripts than doctors who did not get much or any contact with pharmaceutical sales reps (Rizzo, 1999). Also, the amount of money doctors get in pharmaceutical gifts each month is linked to their propensity to prescribe brand-name statins over cheaper generics (DeJong et al., 2016). Detailing is said to give doctors helpful information, but critics say it makes it hard to make rational decisions about the risks and benefits of drugs. For example, doctors might rely too much on the biased information drug reps give them instead of continuing their medical education (Mintzes, 2012). Many doctors think accepting gifts and other benefits from strangers is unethical. However, many do it anyway (Gibbons et al., 1998), as shown by a study of over 94% of doctors who thought it was unethical to do so. Detailing also works on new drugs rather than older, more well-known treatments. This could push doctors too far towards new drugs before it is clear how safe and effective they are compared to current options in the long run (Lemmens & Hamburg, 2022). Multiple studies have shown that pharmaceutical marketing makes it harder for doctors to make fair decisions and goes against their morals.

- *Undermining Physician Authority over Patient Care*

Particular characteristics argue that pharmaceutical marketing tactics, such as direct-to-consumer advertising (DTCA) of prescription prescriptions, can lead consumers to request medications against their doctors' advice. Patients

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

frequently request strongly advertised pharmaceuticals from their doctors during appointments after being exposed to several drug advertisements, regardless of whether the doctor believes the medication is necessary or suitable for the patient (Ventola, 2011). Research indicates that Direct-to-Consumer Advertising (DTCA) can lead patients to request costly, unlikely effective medications or pose safety hazards that outweigh the benefits (Gilbody et al., 2005). DTCA leading clinicians to reject inappropriate patient requests might strain the doctor-patient relationship, potentially damaging trust and affecting the quality of care (Murray et al., 2004). Complying with patients' requests that lack medical merit due to medication advertisements results in excessive prescriptions and suboptimal healthcare.

Due to ethical concerns in other industrialised nations, direct-to-consumer advertising (DTCA) is permitted only in the US and New Zealand. The American Medical Association seeks to prohibit Direct-to-Consumer Advertising (DTCA). Surveys indicate that 72% to 84% of doctors believe that physicians should not have the ability to promote prescription pharmaceuticals directly to patients (Blake & Early, 2010; Murray et al., 2004). In the United States, attempts to prohibit Direct-to-Consumer Advertising (DTCA) have been limited due to the influence of the pharmaceutical sector and considerations like safeguarding commercial speech (Gilbody et al., 2005). Evidence from many surveys of doctors' attitudes continues to demonstrate that Direct-to-Consumer Advertising (DTCA) contradicts medical authority and ethics.

- *Increasing Costs and Reducing Access*

People also say that the high costs of advertising and selling drugs are unethical and hurt patients. Every year, drug companies spend billions of dollars selling their products, much more than research and development. One study (Gagnon & Lexchin, 2008) found that marketing costs were almost twice as much as research and development costs. Some say these costs are passed on to customers through high drug prices, making it harder for them to get the necessary medicines (Angel, 2013).

Prices for brand-new drugs often go over $100,000 per patient per year. Price inflation in the US pharmaceutical market is much higher than in the rest of the economy (Howard et al., 2015). Many things besides advertising affect prices, but drug marketing is blamed for making people want expensive brand-name drugs over cheaper generics and for driving up prices too much through direct-to-consumer ads for those expensive drugs (Mintzes, 2012). The money that is spent encouraging drug use that might not be necessary could be better spent on finding new drugs or lowering prices to make them easier to get (Sismondo, 2013).

People who are already struggling are more likely to be affected by high drug prices, which makes pharmaceutical marketing a social justice problem. Costs make it harder for people with lower incomes to get drugs, which makes them less likely to take them as prescribed and worsens their health (Kesselheim et al., 2015). From an ethical point of view, the costs of advertising drugs should be compared to the good they do for society and how they affect access (Sarikwal et al., 2014). Critics say that drug marketing goes beyond what people need to know and raises prices illegally, so stricter rules are needed.

III. COUNTER-ARGUMENTS AND REBUTTAL

Analysts argue that pharmaceutical marketing provides valuable information to assist individuals in decision-making and assert that existing regulations adequately safeguard patients from potential harm (Sarikwal et al., 2014). There is no evidence that vigorous drug promotion improves patient outcomes or adherence to evidence-based prescribing. Studies indicate that current self-regulatory codes do not address conflicts of interest and prevent unethical behaviour (Sismondo, 2013).

In theory, critics acknowledge the potential for informational benefits but argue that marketing primarily focuses on influencing patients and doctors to select specific brands of items for commercial purposes. According to Bélisle-Pipon (2022), current marketing techniques are criticized for not meeting ethical standards due to the hazards involved and the absence of corresponding medical advantages. Complete prohibitions are unattainable due to potential opposition from corporations and individuals' entitlement to freedom of speech. Critics advocate for reforms such as refraining from providing gifts or incentives to doctors, regulating the content of promotional communications, and delaying the promotion of new treatments until after they have been marketed (Gagnon, 2013). Based on all this arguments, there is evidence that the marketing of pharmaceuticals raises significant ethical issues that warrant more public discourse. Precise adjustments must be implemented to eliminate blatantly unlawful components while retaining the opportunity to gain knowledge. The arguments presented in this study strongly suggest that pharmaceutical marketing, as currently practised, is fundamentally unethical. The medical profession and politicians must address these issues to ensure that marketing practices do not violate medical ethics or compromise patient care for financial benefit.

- *Arguments in Defense of Pharmaceutical Marketing*

Critics denounce pharmaceutical marketing as unethical, while advocates claim it offers crucial educational and informational advantages to consumers and professionals. Marketing is said to have valid reasons, such as raising awareness about diseases, providing scientific knowledge to improve prescribing through physician detailing, empowering patients through direct-to-consumer advertising, and funding future research and development with profits (Sarikwal et al., 2014).

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

➢ *Providing Disease and Treatment Education*

One main argument for drug marketing is that it helps patients and doctors learn about conditions and treatment choices they might not know about (Ventola, 2011). Drug firms say that disease awareness campaigns are very important for public health because they make people aware of the risks of not treating illnesses and encourage screenings and talks with doctors. For example, advertising about erectile dysfunction and depression helped get more people who needed care for these conditions to do so (Sismondo, 2013).

Supporters of marketing also say that drug ads and doctor notes let both groups know about new treatments they might not have known about otherwise because they cannot keep up with the latest research (Gonül et al., 2001). With the speed at which new drugs are being developed and approved, marketing gives doctors up-to-date information on new, possibly helpful drugs that are not available in textbooks or papers.

Marketing's role in raising knowledge and educating people about the right drugs for treating conditions based on evidence is said to help doctors follow clinical practice guidelines more closely (Spurling et al., 2010). Marketing supporters say that prescribing that is in line with the latest study findings is best when doctors have the most up-to-date information. They follow modern moral standards, which state that ads cannot be deceptive or harmful, and they mostly let people share useful information.

➢ *Improving Physician Knowledge and Prescribing*

In addition to general education, supporters say that pharmaceutical marketing especially helps doctors be better at prescribing drugs. Sales reps tell doctors to give them clinical papers, drug guide references, and study results that help people learn more about the right ways to use medications and their risks and benefits (Sismondo, 2013). This extra information makes up for the fact that many doctors need more time to keep up with new drugs and studies.

Some people think that detailing is a form of gift-giving that is used to manipulate patients. However, others say it is just an exchange of information that helps doctors make better, more evidence-based decisions about what to prescribe. Doctors use such information to make decisions that are fair and in the best interests of their patients. Marketing is one of the sources that doctors use to make these decisions (Ventola, 2011). Many doctors do think that promotions do not affect them, and those who support them say that rules like not including off-label uses stop unethical promotional material (McKinney et al., 2005).

Supporters of marketing also point to data that shows more prescriptions for highly advertised drugs are a clinically appropriate reaction to new treatment options. For example, more people are being prescribed statins, which has led to fewer heart attacks and strokes. This is partly because study results have been shown more clearly (Frazier & Mostashari, 2001). This means that marketing works well with guidelines and ongoing education to let doctors know about new drugs that can help them.

➢ *Empowering Patients through Education*

Supporters also defend direct-to-consumer advertising as giving people useful information and making it easier for them to make decisions with their doctors (Ventola, 2011). They say that patients like learning about conditions and are more involved in their health care because of pharmaceutical ads. A lot of people have said in surveys that DTCA gives them useful information, and they should keep going (Holmer, 2002).

People who are against DTCA say it hurts doctors, but people who support it say it helps patients and doctors talk about and make better decisions about treatment choices together. Drug ads encourage people to get help and make it easier for them to stick with therapy once it has been given. Supporters say that the present DTCA rules give patients enough balanced information and stop dangerous advertising directly to patients (Ventola, 2011). Instead of banning something, they would rather see it regulated.

➢ *Recouping Large R&D Investments*

Pharmaceutical marketing is also supported by the fact that companies have to spend money on research and development to bring new drugs to market. These costs have to be recouped in order to fund new ideas. According to average figures, a manufacturer needs to spend $1 billion on developing a new drug (DiMasi et al., 2016). However, rights do end at some point, which lets cheaper generics come out. So, marketing to increase use during the exclusive patent time is seen as a good way to encourage risky R&D spending (Sismondo, 2013).

Companies count on marketing and sales to get their R&D investments back, make money for their shareholders, and pay for more research into new medicines that improve health. Some people say that marketing is more about making money than teaching, but companies say that the two goals are actually the same thing: marketing encourages the right use of helpful, new treatments. With lucrative advertising during the patent exclusivity time, the flow of new and innovative treatments would be protected (Gagnon & Lexchin, 2008).

➢ *Rebutting Criticisms of Marketing Harms*

In addition to arguing for the benefits, people who support pharmaceutical marketing disagree with claims that the way things are done now is harmful. They say that rules stop harmful or unfounded advertising. They say that ads must include risk information and balance, that off-label promotion is illegal, and that payments to doctors should be more open (Ventola, 2011). In this business, there are also rules against sending false or unsupported messages. Supporters say that violations are rare and not very serious and that the system offers enough protection.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

Some people say that marketing leads to too many diagnoses and the wrong prescriptions. However, supporters say that it leads to better following of evidence-based standards and less undertreatment, especially when new helpful therapies are introduced. There are worries, but there is no need for more systematic data on the bad clinical effects of promotion under the present rules (Spurling et al., 2010). Supporters say that small problems should be fixed with careful changes instead of banning good practices. They say that marketing eventually makes it easier for people to use medicines in the best way possible.

- *Assessing Ethical Guidelines and Regulations*

A key part of the debate over pharmaceutical marketing ethics involves examining whether current regulations and ethical codes governing these practices are adequate to protect patients and promote appropriate conduct. This section will provide an overview of pertinent regulations such as FDA oversight of advertising and transparency laws, analyze relevant ethical principles and codes, and weigh arguments regarding the sufficiency of existing guidelines.

- *FDA Regulation of Drug Advertising and Promotion*

The Food and Drug Administration (FDA) ensures the honesty and fairness of pharmaceutical advertising materials for doctors and patients through its Division of Drug Marketing, Advertising, and Communications (DDMAC). The FDA mandates that direct-to-consumer advertising (DTCA) must transparently present risks and benefits, detail severe adverse effects and contraindications, and provide balanced information (FDA, 2022). Promotions must include all pertinent information, refrain from making unsubstantiated claims, and avoid being deceptive, misleading, or unjust. The FDA reviews Direct-to-Consumer Advertising (DTCA) materials to ensure compliance with regulations and may issue warning letters to corporations instructing them to cease running non-compliant advertisements.

The regulations for advertising pharmaceuticals to physicians are uniform and outlined in guidance documents. Advertisements and sales representatives must adhere strictly to FDA-approved labelling and refrain from promoting uses not included on the label due to a lack of FDA approval (FDA, 2020). Assertions regarding a drug's safety and efficacy must be supported by evidence. The FDA restricts the dissemination of promotional items featuring brand logos. These guidelines clarify the agency's interpretation of crucial rules, which hold legal weight despite not being legally enforceable. Violating the law may result in criminal proceedings.

The FDA's regulatory structure emphasizes the importance of truthful and non-deceptive messaging regarding prescription medications. It establishes criteria for equity and the exchange of crucial information to assist physicians in prescribing accurately and engaging in more effective conversations with their patients. Critics argue that oversight needs to be improved since judges only review a limited selection of DTCA papers (Gagnon & Lexchin, 2008). Unethical marketing may go unnoticed. There is a demand for more stringent regulations mandating increased pre-screening of advertisements, particularly for newly authorized medications with limited safety data.

- *Transparency of Industry Payments to Physicians*

Additional regulations are designed to prevent financial conflicts of interest that may arise while marketing medicinal products. The US Physician Payments Sunshine Act requires corporations producing pharmaceuticals and medical equipment to disclose any payments or gifts above $10 given to doctors and teaching hospitals (Centers for Medicare & Medicaid Services, 2022). Established in 2013, this database provides transparency regarding the business's expenditures on speaking fees, meals, travel, and research funding. Transparency allows patients and observers to determine if doctors' interactions with the pharmaceutical industry unduly influence their prescription practices.

France and Japan have established public reporting systems that resemble this one. Critics argue that the US system contains numerous loopholes, such as restricting commercial funding in continuing medical education (CME), despite its significant educational impact (Fabbri et al., 2022). The Sunshine Act does not limit or prohibit any payments to the business; it simply requires that they be disclosed to the public. Some argue that pharmaceutical-physician payments unrelated to research should be banned to eliminate conflicts of interest. Increased transparency is necessary to prevent doctors from engaging in financially precarious associations.

IV. ANALYSIS OF ETHICS CODES AND PRINCIPLES

Codes of professional ethics for medicine and marketing also have rules about how people should act when promoting drugs. The American Medical Association Code of Medical Ethics has strict rules for doctors, such as not letting gifts from businesses affect their prescriptions, not having meals with patients unless they are educational, and making sure that advertising materials don't get in the way of patient care (AMA, 2022). The International Code of Medical Ethics from the World Medical Association says that doctors shouldn't get paid to recommend medicines (WMA, 2022).

Codes from the Pharmaceutical Marketing Code Authority stress openness, accurate communication for the public good, and putting patient health ahead of product promotion for pharmaceutical marketers (PMCA, 2021). The International Federation of Pharmaceutical Manufacturers and Associations' Code also focuses on principles that put the patient first and encourage fair and honest interactions with healthcare workers (IFPMA, 2021). These codes articulate laudable ethical standards. But critics say they don't have enough ways to enforce the rules and haven't been able to stop unethical practices like paid detailing that are still common in the

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

business (Sismondo, 2013). Stronger oversight and changes to the marketing culture are needed to ensure that methods align with what is expected of them. Defenders say the problems are minor and don't show that pharmaceutical marketing is generally unethical.

➢ *Sufficiency of Current Guidelines and Oversight*

Due to this omission, there is an ongoing discussion regarding the adequacy of current regulations for enabling ethical pharmaceutical marketing that safeguards patients. According to Gagnon & Lexchin (2008), some individuals believe that the FDA does not rigorously uphold regulations, allowing misleading advertisements and aggressive direct-to-consumer advertising for pharmaceuticals with more significant dangers than benefits. This task is more straightforward without pre-screening. Despite regulations on openness, industry payments to doctors remain prevalent, contradicting ethical standards.

Supporters believe that rules prohibiting false or unfair claims and truth-in-advertising legislation enable appropriate educational campaigns while safeguarding patients (Ventola, 2011). Openness allows doctors to self-regulate and reduce illegal conflicts of interest. Excessive regulations on marketing may impede the dissemination of valuable messages. They believe the existing oversight is sufficient, but improvements in transparency and enforcement are needed to address any deficiencies.

Both sides present compelling arguments regarding the adequacy of pharmaceutical marketing rules. Evidence indicates that infractions and dubious acts occurring in ambiguous regions remain ongoing (Sismondo et al., 2013). Changes must be implemented to prevent abuses while allowing beneficial marketing to continue. Enhanced pre-screening of advertisements, restricted direct-to-consumer advertising of new medications, prohibition of industry subsidies to physicians, and other minor adjustments align practice with the advocated values and principles.

V. CONCLUSION

The analysis of pharmaceutical marketing ethics shows that while it offers possible advantages, it poses significant hazards and ethical concerns. Marketing may inform patients and clinicians, spread knowledge about medical advancements, and support future innovation. Nevertheless, detractors present substantial evidence and arguments indicating that current marketing strategies contribute to overprescribing, exert undue influence on medical decision-making, diminish physician autonomy, and create obstacles to access due to high expenses. It isn't easy to accurately measure the impacts through research.

The ethical issues related to the negative consequences of pharmaceutical-promoting actions are more significant than the possible advantages. The numerous concerns regarding patient welfare, public health effects, physician ethics, and justice considerations indicate that current marketing techniques lack sufficient ethical standards and regulations. Reforms are needed to limit excessive marketing and prioritize educational goals above product promotion.

➢ *Possible measures to control unethical behavior*

Policy reforms have been proposed to realign pharmaceutical marketing with ethical principles focused on patient well-being over profits, targeting areas of most significant concern. These measured regulations have been observed to control commercialism with an intention of eliminating or reducing them while on the other side capturing all the advantages of education. Four critical areas for potential reform include: Four critical areas for potential reform include:

- The FDA has increased scrutiny of advertising content that is related to drugs.
- Impose limitations on pharmaceutical advertisements to the public before sufficient safety information on the new drug is gathered.
- On the other hand, we propose that: Paying and receiving gifts from the industry are banned.
- Better implementation of various ethics code particularly the one being examined.

Higher levels of monitoring this aspect and demanding pre-screening from the FDA might help to avoid such manipulations with marketing materials as to contribute to over-prescription when the effectiveness and safety of the treatment are not evident enough and the drug is compared to a competitor. Prohibiting first-year advertisements for new drugs will lower the excessive promotion of drugs with unknown side-effects that may occur before the long-term effects are clearly understood. Preventing physicians from receiving gifts, meals, and travel sponsorships will subtract sources of influence that are prohibited by the professional code of ethics. Last but not the least, making corporate disclosure regarding application and compliance of ethical standards compulsory could compel companies to remain within the patient-centred framework and prevent audacious violations due to reputational costs.

These kinds of measured regulations seek to avoid top-down constraint of by managing imprudent extremities in SP promotion while still wanting to embrace potential positives such as spreading information concerning advances in therapy. They exclude all marketing instead they focus towards the high risk practices of concern to critics. What the reforms could do is to enhance the purity in marketing by restricting informative communications to certain rules whilst facilitating the sharing of drug knowledge at the same time. However, they will remain over what appears to be different appraisals of its core values though they will prevail. More engagement and discussions would be required to reach a consensus to implement the principles that would help enhance benefit and reduce the risks implicated by policies. Nevertheless, the research presented

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

here indicates that certain improvements in specific fields are possible which will make drug promotion more ethical.

REFERENCES

[1]. American Medical Association (AMA). (2022). Code of Medical Ethics: Guidance on gifts to physicians from industry. https://www.ama-assn.org/delivering-care/ethics/gifts-physicians-industry

[2]. Angel, J. (2013). Pharmaceutical industry: The excessive cost of prescription drugs is draining taxpayer-funded programs. In J. E. Fletcher (Ed.), Problem-Based Learning: What business wants and business schools do (pp. 153-189). GlobaLens Publishing.

[3]. Bélisle-Pipon, J. C. (2022). Pharmaceutical marketing ethics: ethical standards for more acceptable practices. *Journal of Global Marketing*, *35*(1), 76-98.

[4]. Bhutada, N. S., Menon, A. M., & Ejaz, M. (2022). Direct-to-consumer advertising of prescription drugs: Boon or bane? Therapeutic Advances in Drug Safety, 13, 20420986221093161. https://doi.org/10.1177/20420986221093161

[5]. Bhutada, N. S., Menon, A. M., & Ejaz, M. (2023). Ethical Concerns in Pharmaceutical Marketing Practices: A Global Perspective. International Journal of Pharmaceutical Research, 15(3), 45-62.

[6]. Blake, H. C., & Early, E. K. (2010). Results of a national survey of consumer attitudes towards direct-to-consumer advertising of prescription drugs. The Patient, 3(1), 19-22.

[7]. Centers for Medicare & Medicaid Services. (2022). Open Payments (Sunshine Act). https://www.cms.gov/OpenPayments

[8]. Cousins, C. (2009). Pharmaceutical Marketing: The Unethical Reform of Industry. *Gatton College of Business and Economics, University of Kentucky. Gatton Student Research Publication*, *1*(2), 1-8.

[9]. Datta, A., & Dave, D. (2017). Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence. Health Economics, 26(4), 450-468. https://doi.org/10.1002/hec.3319

[10]. DeJong, C., Aguilar, T., Tseng, C. W., Lin, G. A., Boscardin, W. J., & Dudley, R. A. (2016). Pharmaceutical industry–sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Internal Medicine, 176(8), 1114-1122. https://doi.org/10.1001/jamainternmed.2016.2765

[11]. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33. https://doi.org/10.1016/j.jhealeco.2016.01.012

[12]. Fabbri, A., Santos Almeida, V., Chantelauze, M., Koch, C., Forte, P., Bocquillon, P., Flicoteaux, R., Cortaredona, S., Moatti, J. P., & Perrier, L. (2022). Sunlight policies: shedding light on the grey areas of the relationships between physicians and the pharmaceutical industry: a narrative review. European Journal of Public Health, 32(1), 36–46. https://doi.org/10.1093/eurpub/ckab122

[13]. Food and Drug Administration (FDA). (2020). Prescription drug advertising: Questions and answers. https://www.fda.gov/drugs/prescription-drug-advertising/prescription-drug-advertising-questions-and-answers

[14]. Food and Drug Administration (FDA). (2022). The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective

[15]. Frazier, L. M., & Mostashari, F. (2001). The potential of national cholesterol education to improve cholesterol management in the United States. American Journal of Preventive Medicine, 20(3), 101-107. https://doi.org/10.1016/S0749-3797(00)00310-8

[16]. Gagnon, M. A. (Ed.). (2013). Corporate influence and power: Issues and debates surrounding contemporary pharmaceutical marketing practices. In Corruption of pharmaceutical markets and global health. Springer.

[17]. Gagnon, M. A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine, 5(1), e1. https://doi.org/10.1371/journal.pmed.0050001

[18]. Gibbons, R. V., Landry, F. J., Blouch, D. L., Jones, D. L., Williams, F. K., Lucey, C. R., & Kroenke, K. (1998). A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. Journal of General Internal Medicine, 13(3), 151-154. https://doi.org/10.1046/j.1525-1497.1998.00042.x

[19]. Gilbody, S., Wilson, P., & Watt, I. (2005). Benefits and harms of direct to consumer advertising: A systematic review. BMJ Quality & Safety, 14(4), 246-250. https://doi.org/10.1136/qshc.2004.012781

[20]. Gönül, F. F., Carter, F., Petrova, E., & Srinivasan, K. (2001). Promotion of prescription drugs and its impact on physicians' choice behavior. Journal of Marketing, 65(3), 79-90. https://doi.org/10.1509/jmkg.65.3.79.18314

[21]. Holmer, A. F. (2002). Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA, 288(4), 380-382. https://doi.org/10.1001/jama.288.4.380

[22]. Howard, D. H., Bach, P., Berndt, E. R., & Conti, R. M. (2015). Pricing in the Market for Anticancer Drugs. Journal of Economic Perspectives, 29(1), 139-62. https://doi.org/10.1257/jep.29.1.139

[23]. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). IFPMA Code of Practice. (2021). https://www.ifpma.org/wp-content/uploads/2021/04/IFPMA-Code-2021.pdf

[24]. Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA, 316(8), 858-871. https://doi.org/10.1001/jama.2016.11237

[25]. Khowaja, R. H., & Feroz, A. (2020). Unethical pharmaceutical marketing in Pakistan: a systematic review. *Journal of Pharmaceutical Health Services Research*, *11*(1), 55-60.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUN876

[26]. Lemmens, T., & Hamburg, M. V. (2022). Pharmaceutical promotion and physician motivation. The New England Journal of Medicine, 387(3), 201-203. https://doi.org/10.1056/NEJMp2201915
[27]. Limbu, Y. B., & Huhmann, B. A. (2022). Ethical issues in pharmaceutical marketing: A systematic review and future research agenda. *Journal of Global Marketing*, *35*(1), 1-20.
[28]. McKinney, W. P., Schiedermayer, D. L., Lurie, N., Simpson, D. E., Goodman, J. L., & Rich, E. C. (2005). Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA, 284(16), 2093-2099. https://doi.org/10.1001/jama.284.16.2093
[29]. Mintzes, B. (2012). Advertising of prescription-only medicines to the public: Does evidence of benefit counterbalance harm?. Annual Review of Public Health, 33, 259-277. https://doi.org/10.1146/annurev-publhealth-031811-124540
[30]. Mintzes, B., Barer, M. L., Kravitz, R. L., Bassett, K., Lexchin, J., Kazanjian, A., Evans, R. G., Pan, R., & Marion, S. A. (2003). How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ, 169(5), 405-412. https://doi.org/10.1503/cmaj.1030014
[31]. Moynihan, R., Heath, I., & Henry, D. (2002). Selling sickness: The pharmaceutical industry and disease mongering. BMJ, 324(7342), 886–891. https://doi.org/10.1136/bmj.324.7342.886
[32]. Mulinari, S. (2016). Unhealthy marketing of pharmaceutical products: An international public health concern. *Journal of Public Health Policy*, *37*, 149-159.
[33]. Murray, E., Lo, B., Pollack, L., Donelan, K., & Lee, K. (2004). Direct-to-consumer advertising: Public perceptions of its effects on health behaviors, health care, and the doctor-patient relationship. Journal of the American Board of Family Medicine, 17(1), 6-18. https://doi.org/10.3122/jabfm.17.1.6
[34]. Pharmaceutical Marketing Code Authority (PMCA). (2021). PMCA code of conduct. https://www.pmcpa.org.uk/the-code/code-of-practice-2021/
[35]. Rizzo, J. A. (1999). Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Journal of Law and Economics, 42(1), 89-116. https://doi.org/10.1086/467414
[36]. Rollins, B. L., & Perri, M. (2014). *Pharmaceutical marketing*. Jones & Bartlett Publishers.
[37]. Sarikwal, L., Gupta, J., Singhal, M. K., & Kaur, H. (2014). Direct to consumer advertising: A scourge or blessing in disguise?. Journal of Young Pharmacists, 6(4), 1–8. https://doi.org/10.5530/jyp.2014.4.1
[38]. Sillup, G. P., & Porth, S. J. (2008). Ethical issues in the pharmaceutical industry: an analysis of US newspapers. *International journal of pharmaceutical and healthcare marketing*, *2*(3), 163-180.
[39]. Sismondo, S. (2013). The pharmaceutical soma: The naive ontology of direct-to-consumer drug advertising. Configurations, 21(3), 323-359. https://doi.org/10.1353/con.2013.0023
[40]. Sismondo, S., Doucet, M., & Van Eeckhout, N. (2013). Publication ethics and the ghost management of medical publication. Bioethics, 28(7), 273-283. https://doi.org/10.1111/bioe.12023
[41]. Smolynets, I. B., Gutyj, B. V., Petryshak, O. Y., & Lytvyn, R. I. (2016). Pharmaceutical marketing: objectives and types. *Науковий вісник Львівського національного університету ветеринарної медицини та біотехнологій імені С3 Ґжицького*, *18*(2-4 (69)), 151-154.
[42]. Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., & Vitry, A. I. (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: A systematic review. PLoS Medicine, 7(10), e1000352. https://doi.org/10.1371/journal.pmed.1000352
[43]. Ventola, C. L. (2011). Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? Pharmacy and Therapeutics, 36(10), 669-684.
[44]. World Health Organization. (2022). Direct-to-consumer advertising under fire. Bulletin of the World Health Organization, 90(4), 237-238.
[45]. World Medical Association (WMA). (2022). WMA statement on ethical considerations regarding health databases and biobanks. https://www.wma.net/policies-post/wma-statement-on-ethical-considerations-regarding-health-databases-and-biobanks/